



GP 1643
P#8

ATTORNEY'S DOCKET NO. I0277/7007(HCL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED


AUG 15 2000

Applicant: Newell et al.
Serial No: 09/470,494
Filed: December 22, 1999
For: USE OF CD40 ENGAGEMENT TO ALTER T CELL RECEPTOR USAGE
Examiner: Unassigned
Art Unit: 1643

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 9 day of August, 2000.


Helen C. Lockhart

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:


Transmitted herewith is/are the following document(s):

- ☒ Information Disclosure Statement
- ☒ Form PTO-1449 with Cited References
- ☒ Certificate of Mailing
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If a fee is required, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,


Helen C. Lockhart
Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617) 720-3500

Docket No. I0277/7007 (HCL)
Date: August 9, 2000
XNDD



RECEIVED

AUG 15 2000

TECH CENTER 1600/2900

ATTORNEY'S DOCKET NO: I0277/7007(HCL)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Newell et al.
Serial No: 09/470,494
Filed: December 22, 1999
For: USE OF CD40 ENGAGEMENT TO ALTER T CELL RECEPTOR
USAGE

Examiner: Unassigned
Art Unit: 1643

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 9 day of August, 2000.


Helen C. Lockhart, Reg. No. : 39,248

Commissioner for Patents
Washington, D.C. 20231

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: - Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references

RECEIVED

AUG 15 2000

TECH CENTER 1600/2900

The Applicant hereby makes the following additional information of record in the above-identified application:

The following are related pending U.S. non-provisional applications which do not appear on the 1449 form.

<u>Serial No.</u>	<u>Filing Date</u>
09/277,575	March 26, 1999
09/596,387	June 16, 2000
09/599,760	June 22, 2000

The following are remarks concerning the other information cited:

PART III: Remarks

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.


By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 09/470,494


Art Unit: 1643



Notwithstanding any statements of the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.


An early and favorable action is hereby requested.

Respectfully submitted,
Newell et al., Applicant(s)

By: 
Helen C. Lockhart, Reg No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. I0277/7007(HCL)
Dated: August 9, 2000
xNDD

FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: I0277/7007(HCL)	SERIAL NO.: 09/470,494
	APPLICANT: Newell et al.	
	FILING DATE: December 22, 1999	GROUP: 1643



U.S. PATENT DOCUMENTS							
Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
		5,593,972	01/14/97	Weiner et al.	514	44	
		5,639,939	06/17/97	McCune, III	800	2	
		5,674,492	10/07/97	Armitage et al.	424	144.1	
		5,677,139	10/14/97	Johnson et al.	435	29	
		5,677,165	10/14/97	deBoer et al.	435	240.27	

FOREIGN PATENT DOCUMENTS							
		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
		WO95/09653	04/13/95	Immunex Corporation	A61K	39/395	
		WO95/10540	04/20/95	Immunex Corporation	C07K	16/28	
		WO97/31025	08/28/97	Chiron Corporation	C07K	16/28	
		WO98/03670	01/29/98	Pangenetics B.V.	C12N	15/86	

OTHER ART
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

		Choe, Jongseon et al., Cellular and Molecular Factors That Regulate the Differentiation and Apoptosis of Germinal Center B Cells, <i>Journal of Immunology</i> , 1996, pages 1006-1016
		Fanslow, W.C. et al., Recombinant CD40 Ligand Exerts Potent Biologic Effects on T Cells, <i>Journal of Immunology</i> , 1994, pages 4262-4269
		Foy, T. M. et al., An Essential Role for gp39, the Ligand for CD40, in Thymic Selection, <i>J. Exp. Med.</i> , Vol. 182, November 1995, pages 1377-1388
		Schattner, E. J. et al., CD40 Ligation Induces Apo-1/Fas Expression on Human B Lymphocytes and Facilitates Apoptosis through the Apo-1/Fas Pathway, <i>J. Exp. Med.</i> , Vol. 181, 1995, pages 1557-1565

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant